Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis.

Zhang Y, Wedeh G, He L, Wittner M, Beghi F, Baral V, Launay JM, Bibi S, Doñate F, Kouros-Mehr H, Arock M, Louache F.

Blood Adv. 2019 Feb 26;3(4):633-643. doi: 10.1182/bloodadvances.2018026179.

2.

Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.

Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, Doñate F, Kollmannsberger CK.

Clin Cancer Res. 2018 Sep 15;24(18):4399-4406. doi: 10.1158/1078-0432.CCR-18-0481. Epub 2018 May 30.

3.

Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates.

Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, Yang P, Morrison K, Coleman J, Malik F, Challita-Eid P, Karki S, Aviña H, Hubert R, Capo L, Snyder J, Moon SJ, Luethy R, Mendelsohn BA, Stover DR, Doñate F.

Cancer Res. 2018 Apr 15;78(8):2115-2126. doi: 10.1158/0008-5472.CAN-17-3202. Epub 2018 Jan 30.

4.

Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia.

Zhao H, Gulesserian S, Ganesan SK, Ou J, Morrison K, Zeng Z, Robles V, Snyder J, Do L, Aviña H, Karki S, Stover DR, Doñate F.

Mol Cancer Ther. 2017 Sep;16(9):1877-1886. doi: 10.1158/1535-7163.MCT-16-0710. Epub 2017 Jun 27.

5.

A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise.

Zhao H, Gulesserian S, Malinao MC, Ganesan SK, Song J, Chang MS, Williams MM, Zeng Z, Mattie M, Mendelsohn BA, Stover DR, Doñate F.

Mol Cancer Ther. 2017 Sep;16(9):1866-1876. doi: 10.1158/1535-7163.MCT-17-0133. Epub 2017 May 18.

6.

The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.

Mattie M, Raitano A, Morrison K, Morrison K, An Z, Capo L, Verlinsky A, Leavitt M, Ou J, Nadell R, Aviña H, Guevara C, Malik F, Moser R, Duniho S, Coleman J, Li Y, Pereira DS, Doñate F, Joseph IB, Challita-Eid P, Benjamin D, Stover DR.

Mol Cancer Ther. 2016 Nov;15(11):2679-2687. Epub 2016 Aug 22.

7.

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.

Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Aviña H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR.

Cancer Res. 2016 May 15;76(10):3003-13. doi: 10.1158/0008-5472.CAN-15-1313. Epub 2016 Mar 24.

8.

Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker.

Morrison K, Challita-Eid PM, Raitano A, An Z, Yang P, Abad JD, Liu W, Lortie DR, Snyder JT, Capo L, Verlinsky A, Aviña H, Doñate F, Joseph IB, Pereira DS, Morrison K, Stover DR.

Mol Cancer Ther. 2016 Jun;15(6):1301-10. doi: 10.1158/1535-7163.MCT-15-0570. Epub 2016 Mar 4.

9.

AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.

Doñate F, Raitano A, Morrison K, An Z, Capo L, Aviña H, Karki S, Morrison K, Yang P, Ou J, Moriya R, Shostak Y, Malik F, Nadell R, Liu W, Satpayev D, Atkinson J, Joseph IB, Pereira DS, Challita-Eid PM, Stover DR.

Clin Cancer Res. 2016 Apr 15;22(8):1989-99. doi: 10.1158/1078-0432.CCR-15-1542. Epub 2015 Nov 20.

10.

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR.

Mol Cancer Ther. 2015 Jul;14(7):1650-60. doi: 10.1158/1535-7163.MCT-15-0067. Epub 2015 May 1.

11.

Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP.

PLoS One. 2014 Jan 21;9(1):e85349. doi: 10.1371/journal.pone.0085349. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e99911.

12.

Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method.

Reguero L, Puente N, Elezgarai I, Ramos-Uriarte A, Gerrikagoitia I, Bueno-López JL, Doñate F, Grandes P.

Histochem Cell Biol. 2014 May;141(5):543-50. doi: 10.1007/s00418-013-1174-x. Epub 2013 Dec 18.

PMID:
24346263
13.

An artificial neural network approach for predicting functional outcome in fibromyalgia syndrome after multidisciplinary pain program.

Salgueiro M, Basogain X, Collado A, Torres X, Bilbao J, Doñate F, Aguilera L, Azkue JJ.

Pain Med. 2013 Oct;14(10):1450-60. doi: 10.1111/pme.12185. Epub 2013 Aug 5.

PMID:
23915306
14.

Transient, 5-HT2B receptor-mediated facilitation in neuropathic pain: Up-regulation of PKCγ and engagement of the NMDA receptor in dorsal horn neurons.

Aira Z, Buesa I, García del Caño G, Bilbao J, Doñate F, Zimmermann M, Azkue JJ.

Pain. 2013 Sep;154(9):1865-77. doi: 10.1016/j.pain.2013.06.009. Epub 2013 Jun 12.

PMID:
23769718
15.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.

Cancer Res. 2010 Feb 15;70(4):1573-84. doi: 10.1158/0008-5472.CAN-09-3237. Epub 2010 Feb 9.

16.

Redox-related antimelanoma activity of ATN-224.

Trapp V, Lee K, Doñate F, Mazar AP, Fruehauf JP.

Melanoma Res. 2009 Dec;19(6):350-60. doi: 10.1097/CMR.0b013e32832c6324.

PMID:
22760066
17.

Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.

Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL.

Clin Cancer Res. 2008 Nov 15;14(22):7526-34. doi: 10.1158/1078-0432.CCR-08-0315.

18.

Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling.

Juarez JC, Manuia M, Burnett ME, Betancourt O, Boivin B, Shaw DE, Tonks NK, Mazar AP, Doñate F.

Proc Natl Acad Sci U S A. 2008 May 20;105(20):7147-52. doi: 10.1073/pnas.0709451105. Epub 2008 May 14.

19.

Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.

Doñate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP.

Clin Cancer Res. 2008 Apr 1;14(7):2137-44. doi: 10.1158/1078-0432.CCR-07-4530.

20.

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224).

Doñate F, Juarez JC, Burnett ME, Manuia MM, Guan X, Shaw DE, Smith EL, Timucin C, Braunstein MJ, Batuman OA, Mazar AP.

Br J Cancer. 2008 Feb 26;98(4):776-83. doi: 10.1038/sj.bjc.6604226. Epub 2008 Feb 5.

21.

Use of glycol ethers for selective release of periplasmic proteins from Gram-negative bacteria.

Allen JR, Patkar AY, Frank TC, Donate FA, Chiu YC, Shields JE, Gustafson ME.

Biotechnol Prog. 2007 Sep-Oct;23(5):1163-70. Epub 2007 Aug 31.

PMID:
17760459
22.

Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase.

Allan AL, Gladstone PL, Price ML, Hopkins SA, Juarez JC, Doñate F, Ternansky RJ, Shaw DE, Ganem B, Li Y, Wang W, Ealick S.

J Med Chem. 2006 Dec 28;49(26):7807-15.

PMID:
17181163
23.

Angiogenesis blockade as a new therapeutic approach to experimental colitis.

Danese S, Sans M, Spencer DM, Beck I, Doñate F, Plunkett ML, de la Motte C, Redline R, Shaw DE, Levine AD, Mazar AP, Fiocchi C.

Gut. 2007 Jun;56(6):855-62. Epub 2006 Dec 14.

24.

A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.

Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA.

Mol Cancer Ther. 2006 Sep;5(9):2271-80.

25.

Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1.

Juarez JC, Betancourt O Jr, Pirie-Shepherd SR, Guan X, Price ML, Shaw DE, Mazar AP, Doñate F.

Clin Cancer Res. 2006 Aug 15;12(16):4974-82.

26.

Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5.

McCrae KR, Doñate F, Merkulov S, Sun D, Qi X, Shaw DE.

Curr Cancer Drug Targets. 2005 Nov;5(7):519-28. Review.

PMID:
16305348
27.

Extracellular tropomyosin: a novel common pathway target for anti-angiogenic therapy.

Doñate F, McCrae K, Shaw DE, Mazar AP.

Curr Cancer Drug Targets. 2004 Nov;4(7):543-53. Review.

PMID:
15578912
28.

Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities.

Doñate F, Juarez JC, Guan X, Shipulina NV, Plunkett ML, Tel-Tsur Z, Shaw DE, Morgan WT, Mazar AP.

Cancer Res. 2004 Aug 15;64(16):5812-7.

29.

Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells.

Guan X, Juarez JC, Qi X, Shipulina NV, Shaw DE, Morgan WT, McCrae KR, Mazar AP, Doñate F.

Thromb Haemost. 2004 Aug;92(2):403-12.

PMID:
15269838
30.

A hybrid fibronectin motif protein as an integrin targeting selective tumor vascular thrombogen.

Liu C, Dickinson C, Shobe J, Doñate F, Ruf W, Edgington T.

Mol Cancer Ther. 2004 Jul;3(7):793-801.

31.

Design of novel N-(2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model.

Price ML, Guida WC, Jackson TE, Nydick JA, Gladstone PL, Juarez JC, Doñate F, Ternansky RJ.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):107-10.

PMID:
12467627
32.

Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.

Liu C, Huang H, Doñate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, Edgington TS.

Cancer Res. 2002 Oct 1;62(19):5470-5.

33.

Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.

Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Doñate F.

Cancer Res. 2002 Sep 15;62(18):5344-50.

34.

The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin.

Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, Pang YP, McCrae KR.

Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12224-9. Epub 2002 Aug 26.

35.

Inhibition of cell migration and angiogenesis by the amino-terminal fragment of 24kD basic fibroblast growth factor.

Ding L, Doñate F, Parry GC, Guan X, Maher P, Levin EG.

J Biol Chem. 2002 Aug 23;277(34):31056-61. Epub 2002 Jun 12.

36.

Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides.

Zhang JC, Qi X, Juarez J, Plunkett M, Donaté F, Sakthivel R, Mazar AP, McCrae KR.

Can J Physiol Pharmacol. 2002 Feb;80(2):85-90.

PMID:
11934260
37.
38.

Interaction of the precursor to mitochondrial aspartate aminotransferase and its presequence peptide with model membranes.

Donate F, Yañez AJ, Iriarte A, Martinez-Carrion M.

J Biol Chem. 2000 Nov 3;275(44):34147-56.

39.

Immunolocalization of the mGluR1b splice variant of the metabotropic glutamate receptor 1 at parallel fiber-Purkinje cell synapses in the rat cerebellar cortex.

Mateos JM, Benítez R, Elezgarai I, Azkue JJ, Lázaro E, Osorio A, Bilbao A, Doñate F, Sarría R, Conquet F, Ferraguti F, Kuhn R, Knöpfel T, Grandes P.

J Neurochem. 2000 Mar;74(3):1301-9.

40.

Opposite behavior of two isozymes when refolding in the presence of non-ionic detergents.

Doñate F, Artigues A, Iriarte A, Martinez-Carrion M.

Protein Sci. 1998 Aug;7(8):1811-20.

41.

Study on the histamine-like activity of guanfacine.

Martinez-Mir MI, Doñate F, Estañ L, Morales-Olivas FJ, Rubio E.

J Pharm Pharmacol. 1990 Aug;42(8):591-2.

PMID:
1981592

Supplemental Content

Loading ...
Support Center